Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today ann ...

Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and mark ...

Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (N ...

Core Insights - Biomerica, Inc. announced real-world results demonstrating the effectiveness of its inFoods IBS product, which includes a new real-time patient feedback system to enhance symptom tracking and improve patient outcomes [1][2] Group 1: Product Effectiveness - The initial analysis from over 360 patients showed an average reduction of 48.5% in gastrointestinal pain and 49.8% in bloating over an 8-week period [6][7] - The real-world outcomes align with and in some cases exceed results from prior randomized clinical trials conducted at leading U.S. medical centers [1] Group 2: Real-Time Feedback System - Biomerica's HIPAA-compliant platform provides physicians with visibility into patient-reported outcomes, allowing for data-informed decisions and adjustments to treatment plans [2] - The real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes [6] Group 3: Market Need and Impact - IBS affects an estimated 10% to 15% of adults in the U.S., leading to decreased quality of life and reliance on medications with adverse side effects [4] - The inFoods IBS product offers a novel diagnostic-guided solution that identifies individual food triggers, enabling targeted dietary changes without pharmaceuticals [4][5] Group 4: Clinical Validation - Peer-reviewed results published in Gastroenterology indicated that patients on an inFoods IBS-guided diet experienced significantly more abdominal pain relief compared to those on a placebo diet (59.6% vs. 42.1%, p-value=0.02) [3]

Core Insights - Biomerica, Inc. has submitted an application for a Proprietary Laboratory Analysis (PLA) code for its inFoods IBS diagnostic test, aiming to enhance patient access and insurance reimbursement for the test [1][2][3] Group 1: Product and Market Overview - The inFoods IBS test identifies patient-specific foods that trigger IBS symptoms such as bloating, abdominal pain, diarrhea, and constipation, providing a personalized approach to treatment [1][3] - IBS affects approximately 10% to 15% of adults in the U.S., leading to significant healthcare costs, indicating a substantial market opportunity for effective management solutions [4] - The inFoods platform addresses an unmet need for personalized management strategies in the IBS market, differentiating itself from traditional trial-and-error diets and symptom-suppressing medications [3][4] Group 2: Clinical Validation and Adoption - A randomized clinical trial published in a leading medical journal demonstrated that patients following a personalized diet based on inFoods test results experienced significantly greater symptom relief compared to those on a placebo diet, highlighting the clinical potential of the platform [5] - Biomerica is collaborating with leading gastroenterology groups and healthcare systems to promote the adoption of the inFoods IBS test, which is also available for direct-to-consumer ordering [6] Group 3: Strategic Goals and Long-Term Vision - The application for the PLA code is part of Biomerica's broader commercialization strategy to facilitate access to the inFoods IBS test and enhance transparency in claims submission [2][3] - The company believes that insurance reimbursement, supported by clinical validation, positions inFoods IBS as a category-defining diagnostic, contributing to long-term value creation [7][8]

Core Viewpoint - Biomerica, Inc. has received regulatory approval for its Fortel Ulcer Test in the UAE, enabling the introduction of a rapid diagnostic tool for Helicobacter pylori infection, addressing a significant public health concern in the region [1][5]. Group 1: Product Overview - The Fortel Ulcer Test is a quick and user-friendly diagnostic tool that detects antibodies to H. pylori, providing accurate results in just 10 minutes [2][8]. - H. pylori infection is linked to various gastrointestinal diseases, including peptic ulcers, dyspepsia, and gastric cancer, with approximately 80% of gastric cancer cases attributed to this bacterium [4][8]. Group 2: Market Context - H. pylori infects about 35% of the U.S. population and 45% in the five largest European countries, with local studies in the UAE estimating infection rates exceeding 50% [3]. - The World Health Organization has classified H. pylori as a Class 1 carcinogen and identified it as one of the top 16 antibiotic-resistant bacteria posing a significant health threat [4]. Group 3: Strategic Impact - The approval of the Fortel Ulcer Test enhances Biomerica's presence in the Middle East, following the successful launch of other diagnostic products [5]. - The company is collaborating with local distributors and healthcare providers to ensure the availability of the Fortel Ulcer Test throughout the UAE [5][6]. Group 4: Company Mission - Biomerica is focused on delivering affordable and innovative diagnostic tools aimed at improving patient outcomes through early disease detection [6][7]. - The Fortel Ulcer Test aligns with the company's mission to enhance global health by providing fast and accessible diagnostics [6].

Core Insights - Biomerica, Inc. has received regulatory approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test, enabling the introduction of this rapid diagnostic tool for H. pylori infection in the UAE [1][5] - The Fortel® Ulcer Test is designed to detect antibodies to H. pylori, providing accurate results in just 10 minutes, which is crucial for timely medical intervention [2][8] - H. pylori infection rates are notably high in the UAE, with local studies estimating rates exceeding 50%, leading to significant health concerns including peptic ulcers and gastric cancer [3][4] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases [7] - The company aims to improve patient outcomes through early disease detection and affordable diagnostic tools, exemplified by the Fortel® Ulcer Test [6][7] - Biomerica is expanding its presence in the Middle East, collaborating with local distributors and healthcare providers to enhance access to its diagnostic products [5][6]

Core Insights - Biomerica, Inc. has received approval from the UAE Ministry of Health and Prevention for its Fortel Kidney Disease (Microalbumin) Test, enabling its sale in a region with a high prevalence of chronic kidney disease (CKD) [1][8] - The Fortel Kidney Disease Test is a rapid diagnostic tool that provides results in 10 minutes using a urine sample, allowing for early detection of kidney disease [2][8] - CKD is a significant global public health issue, with over 80% of at-risk patients undiagnosed, and is projected to be the 5th leading cause of years of life lost by 2040 [2][8] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for point-of-care and clinical laboratory use [7] - The company aims to enhance health and well-being while reducing healthcare costs, with a particular focus on gastrointestinal and inflammatory diseases [7] Market Context - In the UAE, diabetes and hypertension are major risk factors for CKD, with over 12% of adults living with diabetes and 29% to 35% estimated to have hypertension [4] - CKD is often asymptomatic until advanced stages, making early detection crucial for effective intervention [4][5] Strategic Initiatives - The approval of the Fortel Kidney Disease Test supports Biomerica's mission to provide life-saving diagnostic tools in high-need areas, particularly in the Middle East [5][6] - The company has established partnerships with leading distributors and healthcare providers in the UAE to ensure the test's availability across the country [5]

Core Insights - Biomerica, Inc. has received approval from the UAE Ministry of Health and Prevention for its Fortel® Kidney Disease (Microalbumin) Test, enabling its sale across the UAE, a region with a high prevalence of chronic kidney disease (CKD) [1][8] - The Fortel® Kidney Disease Test is a rapid diagnostic tool that provides results in 10 minutes using a urine sample, allowing for early detection of kidney disease, particularly in high-risk populations [2][4] - CKD is a significant global public health issue, with over 80% of at-risk patients undiagnosed, and is projected to be the 5th leading cause of years of life lost globally by 2040 [2][4] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases [7] - The company aims to enhance health outcomes while reducing healthcare costs through its innovative diagnostic solutions [7][6] - Biomerica has established partnerships with distributors and healthcare providers in the UAE to ensure the availability of the Fortel® Kidney Disease Test across the country [5] Market Context - In the UAE, diabetes and hypertension are major risk factors for CKD, with over 12% of adults living with diabetes and an estimated 29% to 35% of the population having hypertension [4] - The approval of the Fortel® Kidney Disease Test addresses a critical need for preventative healthcare in a region where these conditions are prevalent [5][8] - Early detection through the Fortel® test can lead to timely interventions, potentially reducing the economic burden associated with CKD progression [3]

Core Viewpoint - Biomerica, Inc. will implement a 1-for-8 reverse stock split to increase the bid price of its common stock and regain compliance with Nasdaq's minimum bid price requirement [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern time on April 21, 2025, with trading on a split-adjusted basis starting the same day [1]. - The number of shares outstanding will decrease from approximately 20,366,095 shares to about 2,545,762 shares, while the number of authorized shares will remain unchanged [3]. - Stockholders will automatically have fractional shares rounded up to the next whole share, and adjustments will be made to equity awards and option exercise prices accordingly [3][4]. Group 2: Compliance and Authorization - The reverse stock split was authorized by Biomerica's stockholders during the 2024 Annual Meeting held on December 13, 2024, with the final ratio determined by the Board of Directors [2]. - The company aims to enhance its stock price to meet Nasdaq's listing requirements, which is critical for its continued presence on the exchange [2]. Group 3: Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [6]. - The company markets products designed to improve health outcomes while reducing healthcare costs, with a strong emphasis on point-of-care testing [6].